News

Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs
The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...
Novo Nordisk announces CEO transition as share price slips
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...
Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...
Zacks Investment Research on MSN1d
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
Ignore The Noise - Novo Nordisk Is A Clear Buy
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
Indianapolis Business Journal2d
Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
Health on MSN3d
Ozempic Shows Promise in Treating a Severe Form of Liver Disease, Study Finds
A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...
Novo Nordisk A/S (NVO): A Bull Case Theory
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will ...